CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

questionnaire assesmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug479 COVID-19 patients Wiki 0.45
drug883 Exercise brochure Wiki 0.45
drug2465 Telerehabilitation Wiki 0.22
drug791 Doxycycline Wiki 0.22
drug1822 Placebo Wiki 0.03

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D003095 Collagen Diseases NIH 0.45
D012216 Rheumatic Diseases NIH 0.40
D059350 Chronic Pain NIH 0.37
D012213 Rheumatic Fever NIH 0.32
D001172 Arthritis, Rheumatoid NIH 0.17
D001168 Arthritis NIH 0.13
D013315 Stress, Psychological NIH 0.10

Correlated HPO Terms (3)

Name (Synonyms) Correlation
HP:0012532 Chronic pain HPO 0.37
HP:0001370 Rheumatoid arthritis HPO 0.17
HP:0001369 Arthritis HPO 0.13

There are 5 clinical trials

Clinical Trials

1 Distress During the COVID-19 Pandemic in France: a National Assessment of At-risk Populations

There are many scales for screening or assessing the impact of a disease. These scales are generally used to diagnose or assess the severity of a disease and are carried out at the request of a physician by the patient. Conversational agents could make it possible to administer these questionnaires remotely, analyse them and use the results on a large scale, without prior medical intervention. The main objective of this study is to quantify and qualify the distress of a large population in times of pandemic crisis.

NCT04337047 Stress, Psychological Other: questionnaire assesment
MeSH:Stress, Psychological

Primary Outcomes

Measure: quantify and qualify distress over a large population in times of pandemic crisis.

Time: 1 month

Secondary Outcomes

Measure: qualify demographic data vs distress over a large population in times of pandemic crisis.

Time: 1 month

2 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak

Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.

NCT04351399 Sars-CoV2 Rheumatic Diseases Rheumatoid Arthritis Chronic Pain Other: questionnaire assesment
MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain
HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Measure: Frequency of RA patients with emotional impact (feeling of isolation)

Time: maximum 1 week from baseline on

Secondary Outcomes

Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.

Measure: self-reported questionnaire for painful

Time: maximum 1 week from baseline on

3 Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak

In the context of quarantine with COVID-19, we wish to study the experience and psychological impact in adult patients living with osteoporosis.

NCT04351633 Sars-CoV2 Osteoporosis Other: questionnaire assesment
MeSH:Osteoporosis

Primary Outcomes

Measure: percentage of patient with feeling of disabilities

Time: maximum 1 week from baseline on

4 Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak

In the context of quarantine with COVID-19, we will study the experience and psychological impact of pain in adult patients living with chronic pain. We will evaluate the link between the question of physical and psychological confinement in the experience of pain in this particular situation

NCT04353011 Sars-CoV2 Chronic Pain Other: questionnaire assesment
MeSH:Chronic Pain
HPO:Chronic pain

Primary Outcomes

Measure: Hospital Anxiety and Depression Scale questionnaire

Time: 1 week from baseline on

Secondary Outcomes

Measure: Quality of life (SF36)

Time: 1 week from baseline on

Measure: self-reported questionnaire for painful

Time: 1 week from baseline on

Measure: qualitive questionnaire

Time: 1 week from baseline on

5 Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants

A retrospective monocentric study with large active files of patients monitored for rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus with as main endpoint the morbimortality of Covid-19 in these patients (number of patients hospitalized in conventional units and/or in intensive care and/or deceased). The results will be compared with those of the general population based on the epidemiological data of Covid-19.

NCT04426279 Sars-CoV2 Rheumatoid Arthritis Rheumatic Diseases Other: questionnaire assesment
MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases

Primary Outcomes

Description: The diagnosis of Covid-19 is either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology. The results will be compared with those of the general population based on Covid-19 epidemiological data.

Measure: the number of patients with severe Covid-19 who were admitted to a conventional unit and/or an ICU and/or deceased, during the Covid-19 epidemic wave (from March to August 2020) among patients with IRC under IS.

Time: At 6 months

Secondary Outcomes

Measure: Diagnosis of Covid-19 either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology.

Time: At 6 months

Measure: The number of patients admitted to conventional unit and/or ICU and/or deceased among patients with IRC under IS between the Covid-19 epidemic wave (March to August 2020) and the six-month period preceding it (September to February 2020).

Time: At 6 months

Description: Treatment modification will be assessed by the number of weeks of treatment not taken, the number of injections not given, the number of delayed or missed infusions. Among those who have modified or stopped their treatment, the impact on their diseases will be evaluated by the loss of remission, the patient's opinion on the notion of relapse, the increase or initiation of corticosteroid therapy and the substantive change in treatment.

Measure: The number of patients who maintained, modified, or discontinued their treatment.

Time: At 6 months

Related HPO nodes (Using clinical trials)

HP:0001369: Arthritis
Genes 263
CCN6 IL2RA NFKBIL1 LBR SPTB BLNK TRAPPC2 EPB42 MVK CD79A IL36RN COMP STAT3 IL2RB TGFB3 MEFV IL12A-AS1 CASP10 MLX MMP13 SLCO2A1 COL2A1 COL2A1 ASAH1 IGHM COL2A1 APOE HNF4A COL2A1 ADA2 PTPN22 MMP14 NOD2 CD247 BTK SCARB2 COL2A1 GLA UMOD CCR1 COL11A2 LRBA CCR6 COMP EXT1 IL6 RREB1 KLRC4 COL11A1 PTPN22 PSTPIP1 HNF1B SAMHD1 HLA-C COL11A2 LRP6 GPR101 COL2A1 RAG1 KIF7 DCLRE1C NOD2 CTLA4 NLRP3 HPRT1 ABCG8 HGD MMP13 HLA-DRB1 NLRP3 SH3KBP1 SLC37A4 TF CCN6 ZNF687 GJB2 IL2RA PFKM AIP FASLG TREX1 HLA-B MATN3 ASPN TNFRSF1A C4A COL2A1 MYH14 UBAC2 FAS ARVCF ACP5 EXT2 PRG4 AEBP1 MTHFD1 ANKRD55 PTPN22 TFR2 GCH1 GJB6 COL9A1 COL11A2 PTPN22 SPP1 RNASEH2B TRAPPC2 OCRL TREX1 LRRC8A GBA COL1A1 LMX1B ACAN GP1BB TLR4 ANK1 COMP UFD1 SLC12A3 NLRP3 FAS HGD IL12A SEC61A1 PHEX COPA HPGD IRF5 FCGR2B TRPV4 PSMB9 WIPF1 CTLA4 CAV1 MVK HLA-DRB1 ATP7B MUC1 COL9A1 ACAN ATP7B EPCAM DNASE1L3 CLCNKB LMNA MMP2 IL10 IL12B RASGRP1 PTPN2 COMT COL2A1 STAT4 SLC37A4 GNAS MIF HLA-DRB1 WAS STAT4 RNF168 CLCN7 JMJD1C IL23R MEFV G6PC CFI ERAP1 F8 PSTPIP1 GHR HLA-B HIRA PRPS1 ADAR DNAJB11 MEFV PTPN2 IL10 ANKH IFIH1 STAT4 COL5A1 FRZB HPGD KIF22 TBX1 CIITA CD79B IGLL1 IRAK1 IL2RB MATN3 COL9A2 COL9A3 TNFRSF11B COMP HLA-B STAT4 PADI4 MATN3 HJV COL2A1 SMAD3 F9 TRPS1 UFSP2 RAG2 COL1A1 MEFV COL5A1 ANKRD55 SLC40A1 SLC4A1 SPTA1 FBN1 BTK RNASEH2C DNASE1 CANT1 TBX1 PHEX CD247 TCF3 PSMB4 PIK3R1 AGA CD244 COL5A2 LEMD3 FGFR3 RNASEH2A ACAN HPRT1 ANKH SEC24C GDF5 SLC22A4 UMOD HPRT1 TRPV4 HPGD BTK FAS COL9A3 UFSP2 ZMPSTE24 PTPN22 LACC1 HPRT1 NLRP3 HNF1B HOXD10 PRKCD SLC26A2 COL9A2 SMAD3 FCGR2A CCN2 CLCN7 COL3A1 ASAH1 NLRP12
Protein Mutations 4
A147T N363S R620W V600E
SNP 10
rs2246704 rs2853884 rs35705950 rs3747158 rs3790515 rs3828057 rs4820059 rs7291050 rs933226 rs9826
HP:0012532: Chronic pain
Genes 3
TGFB2 ATXN3 FLVCR1
Protein Mutations 1
K15210D
SNP 2
rs1042713 rs12654788
HP:0005764: Polyarticular arthritis
Genes 13
ANKRD55 CD247 STAT4 NOD2 NLRP1 IL2RA DMP1 ENPP1 TNFAIP3 MEFV IL2RB PTPN2 PTPN22
Protein Mutations 0
SNP 0
HP:0001370: Rheumatoid arthritis
Genes 28
ANKRD55 IL2RA NFKBIL1 CD247 GCH1 STAT4 PADI4 SLC22A4 IL2RA ANKRD55 IL6 PTPN2 IL2RB IL10 STAT4 HLA-DRB1 PTPN22 PTPN22 LACC1 ACP5 DCLRE1C CIITA CD247 PTPN2 MIF CD244 IL2RB PTPN22
Protein Mutations 4
A147T N363S R620W V600E
SNP 10
rs2246704 rs2853884 rs35705950 rs3747158 rs3790515 rs3828057 rs4820059 rs7291050 rs933226 rs9826